Hisamitsu Pharmaceutical Co Inc (4530.T)
22 Nov 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|80||2015||Chairman of the Board, Chief Executive Officer, Representative Director|
|44||2015||President, Chief Operating Officer, Representative Director|
|62||2016||Executive Officer, Chief Director of BU, Director of Finance, Manager of IR Office, President of Subsidiary, Director|
|54||2016||Chairman of Subsidiary, Director|
|65||2016||Senior Managing Director, Executive Officer|
- BRIEF-Noven files patent infringement lawsuit against Alvogen
- BRIEF-Hisamitsu Pharmaceutical's operating profit probably shrank 3 percent to 12.5 billion yen - Nikkei
- BRIEF-Hisamitsu Pharmaceutical to set up subsidiary in China
- BRIEF-Hisamitsu Pharmaceutical's sales for March-May qtr seen down 8 pct - Nikkei